AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022, dedicated to fighting severe bacterial infections and antimicrobial resistance (AMR) in hospital settings. The company aims to develop innovative medicines and diagnostics to address high unmet medical needs related to bacterial infections, sepsis, and respiratory infections, with a focus on precision medicine and rapid diagnostics. It collaborates with leading organizations like Boehringer Ingelheim, bioMérieux, and Evotec, and is committed to advancing its pipeline through research, clinical trials, and commercialization to improve patient outcomes and combat the global threat of AMR.
Industries
Nr. of Employees
small (1-50)
AUROBAC THERAPEUTICS
Patents
Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
US-12144845-B2
View DetailsIdentification of lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa
US-12121568-B2
View DetailsGram-negative lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof in human serum
US-11773140-B2
View Details
Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
US-12144845-B2
View DetailsIdentification of lysins and derivatives thereof with bactericidal activity against Pseudomonas aeruginosa
US-12121568-B2
View DetailsGram-negative lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof in human serum
US-11773140-B2
View DetailsProducts
Small-molecule therapeutic for septic shock (NCE)
New chemical entity program targeting mechanisms that preserve vascular integrity in early septic shock, developed from discovery through early clinical phases.
Engineered enzymatic biologic for Gram-negative HAP/VAP
Biologic agent engineered to be active against multiple clinically relevant Gram-negative pathogens intended for first-line therapy in hospital-acquired and ventilator-associated pneumonia.
Drug discovery platforms for antimicrobial peptides and microbial-origin leads
Internal and collaborative discovery programs to identify and advance novel antimicrobial peptides and natural-product-derived leads for Gram-negative infections.
Small-molecule therapeutic for septic shock (NCE)
New chemical entity program targeting mechanisms that preserve vascular integrity in early septic shock, developed from discovery through early clinical phases.
Engineered enzymatic biologic for Gram-negative HAP/VAP
Biologic agent engineered to be active against multiple clinically relevant Gram-negative pathogens intended for first-line therapy in hospital-acquired and ventilator-associated pneumonia.
Drug discovery platforms for antimicrobial peptides and microbial-origin leads
Internal and collaborative discovery programs to identify and advance novel antimicrobial peptides and natural-product-derived leads for Gram-negative infections.
Services
Evaluation and execution of collaborations including R&D consortia, academic cooperation, co-development, licensing and acquisition to advance early-stage antimicrobial programs.
Support for progressing discovery-stage assets through preclinical studies and early clinical trials including program management and advisory input.
Formal intake channel for submission of collaboration proposals, including technology/program descriptions and supporting files via a contact form.
Evaluation and execution of collaborations including R&D consortia, academic cooperation, co-development, licensing and acquisition to advance early-stage antimicrobial programs.
Support for progressing discovery-stage assets through preclinical studies and early clinical trials including program management and advisory input.
Formal intake channel for submission of collaboration proposals, including technology/program descriptions and supporting files via a contact form.
Expertise Areas
- Antimicrobial drug discovery
- Biologic antimicrobial development
- Preclinical development
- Early-phase clinical development (Phase I/II)
Key Technologies
- Engineered lysins
- Antimicrobial peptides
- Small-molecule NCE discovery
- Rapid actionable diagnostics integration
News & Updates
John P. O’Donnell has joined the company as Chief Development Officer, in the newly formed subsidiary of AUROBAC THERAPEUTICS in the USA.
The newly formed SAB chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy.
AUROBAC’s strategy aims to address high unmet medical needs in hospital infections, with a focus on innovative pipeline and diagnostics.
Welcoming Dr. Manos Perros as Chairman of the Board and Dr. Marco Taglietti as an Independent Member.
Martin Everett joins AUROBAC with strong expertise to help achieve its goals in antimicrobial resistance.
Florence Séjourné is an experienced biotech leader appointed as CEO to lead AUROBAC.
John P. O’Donnell has joined the company as Chief Development Officer, in the newly formed subsidiary of AUROBAC THERAPEUTICS in the USA.
The newly formed SAB chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy.
AUROBAC’s strategy aims to address high unmet medical needs in hospital infections, with a focus on innovative pipeline and diagnostics.
Welcoming Dr. Manos Perros as Chairman of the Board and Dr. Marco Taglietti as an Independent Member.
Martin Everett joins AUROBAC with strong expertise to help achieve its goals in antimicrobial resistance.
Florence Séjourné is an experienced biotech leader appointed as CEO to lead AUROBAC.